Literature DB >> 2484290

Serum interferon activity of patients with leishmaniasis.

M Barral-Netto1, R Diez, R Badaró, D Sampaio, A Barral, E M Carvalho, E Falcoff.   

Abstract

Serum from a significant proportion of 29 cutaneous and 12 mucocutaneous leishmaniasis patients exhibited interferon activity in a cytopathic assay: positive tests were obtained for 24.1% and 41.7% of the patients, respectively. Similar positive frequencies were observed in other parasitic diseases (schistosomiasis, 12.5%; toxoplasmosis, 20%; Chagas' disease, 16%; leprosy, 12.5%; tuberculosis, 30%). In contrast, none of the 44 serum samples from American visceral leishmaniasis (AVL) patients had interferon activity during the active stage of the disease. However, 13% of the samples obtained from patients recovered from AVL were positive.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2484290

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  3 in total

1.  Bone marrow parasite burden among patients with New World kala-azar is associated with disease severity.

Authors:  Joyce M Silva; Danielle A Zacarias; Lívio C de Figueirêdo; Maria Regiane A Soares; Edna A Y Ishikawa; Dorcas L Costa; Carlos H N Costa
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

2.  Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis.

Authors:  Arlene Caldas; Cecília Favali; Dorlene Aquino; Vera Vinhas; Johan van Weyenbergh; Cláudia Brodskyn; Jackson Costa; Manoel Barral-Netto; Aldina Barral
Journal:  BMC Infect Dis       Date:  2005-12-19       Impact factor: 3.090

3.  High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis.

Authors:  Fabrícia Alvisi de Oliveira; Carla Vanessa Oliveira Silva; Nayra Prata Damascena; Rodrigo Oliveira Passos; Malcolm S Duthie; Jeffrey A Guderian; Ajay Bhatia; Tatiana Rodrigues de Moura; Steven G Reed; Roque Pacheco de Almeida; Amélia Ribeiro de Jesus
Journal:  BMC Infect Dis       Date:  2013-07-19       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.